VivoSim Labs to Showcase Breakthrough Multiparametric

New Post Public Reply Private Reply Replies (0) Message Board
louied91
59
VivoSim Labs to Showcase Breakthrough Multiparametric NAMkind™ Liver and Intestine Data at the 2026 American College of Toxicology (ACT) Annual Meeting

https://www.globenewswire.com/news-release/20...eting.html

New data on 10 compounds pulled due to unforeseen liver tox highlight how VivoSim’s models often easily catch clinical failure risk missed by animal models, using a complex approach that leverages several parameters studied simultaneously

SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc., (Nasdaq: VIVS) (the “Company” or “VivoSim”), a leader and pioneer in next generation human-relevant New Approach Methodologies (NAMs) 3d human cellular models for preclinical safety and translational efficacy, announced today that its scientific team is presenting two landmark studies at the 2026 American College of Toxicology (ACT) Annual Meeting, taking place November 15–18 in San Antonio, Texas.

The presentations underscore the transformative power of VivoSim’s multiparametric approach across its proprietary NAMkind™ Liver and NAMkind™ Intestine platforms. Instead of measuring solely cell death, VivoSim sets a new standard by integrating multiple complementary endpoints with extended repeat-dose experimentation.

VivoSim’s models successfully characterized complex mechanisms of drug-induced liver injury (DILI) and gastrointestinal toxicity, including compounds discontinued in clinical development and advanced modalities such as antibody-drug conjugates (ADCs) and CDK inhibitors.

Previously, VivoSim provided data from older, classic liver toxicity benchmark compounds, but in San Antonio the company is presenting data on 10 newly tested compounds. Each of these compounds was a drug candidate that passed its nonclinical safety package, including conventional animal studies—the standard, commonly used route to first-in-human trials. These compounds were therefore cleared to enter human trials, where liver safety signals later emerged and development was halted in mid- to late-stage clinical trials. Conventional preclinical methods missed these liabilities, yet VivoSim’s 3D human model and multiparametric methodology in this experiment clearly flag all 10. This work demonstrates the immediate, real-world value of our platform in preventing costly clinical attrition today. Used ahead of first-in-human studies, testing in NAMkind™ Liver can flag liver liabilities while there is still time to redesign or drop a candidate, and help reduce costly liver-related clinical failures.

Multiparametric Resolution of Clinical Attrition in Liver Spheroids

In the first study (Poster #P419: NAMkind™ Liver Multiparametric Analysis Detects Liver Injury Signals in Drug Candidates Discontinued During Early Clinical Development), VivoSim evaluated 10 clinical drug candidates that successfully cleared conventional nonclinical animal safety studies but were later discontinued due to human hepatotoxicity.

Using the 3D human primary liver spheroid platform under 17-day repeated dosing, researchers tracked four complementary endpoints: ATP (metabolic/mitochondrial stress), albumin (hepatocyte function), total glutathione (GSH; oxidative stress), and lactate dehydrogenase (LDH; membrane lysis).

Cmax-normalized margin of safety (MOS) radar profiles successfully identified injury-related signals across all 10 discontinued candidates, spanning metabolic/lipid handling, aldehyde oxidase biotransformation, mitochondrial disruption, and undefined mechanisms.

"Traditional single-endpoint assays and animal models frequently fail to capture delayed or human-specific metabolic liabilities," said Dr. Amar A. Sethi, Chief Scientific Officer at VivoSim Labs. "By applying a rigorous multiparametric approach in NAMkind™ Liver, we are able to look beyond basic cell viability and map out the exact convergence of various tissue stresses (functional, oxidative, and metabolic). This gives sponsors actionable mechanistic insight into liver toxicity risk margins long before clinical trials begin."

Decoding Regional and Culture-State Intestinal Vulnerabilities

In the second study (Poster #P421: NAMkind™ Intestine Profiles Region- and Culture-State-Dependent Epithelial Liabilities of CDK Inhibitors and Tubulin Inhibitor-Linked ADCs), VivoSim demonstrated how polarized human colon and ileum models in both proliferative and differentiated states capture complex gastrointestinal toxicities.

Evaluating five cyclin-dependent kinase (CDK) inhibitors and deruxtecan and vedotin-linked ADCs across transepithelial electrical resistance (TEER), Alamar Blue (metabolic competence), and CTG ATP (viability), the study revealed:

Despite sharing cell-cycle pharmacology, CDK inhibitors exhibited highly diverse regional and endpoint-specific MOS profiles that mirrored clinical diarrhea incidence and severity.
Proliferative cultures demonstrated heightened barrier susceptibility (TEER), whereas differentiated cultures highlighted distinct metabolic-competence sensitivities, proving that epithelial cellular state profoundly influences toxicity manifestation.
Histological and functional readouts confirmed concentration-dependent architectural disruption and severe barrier breakdown caused by vedotin payloads in differentiated colon epithelium.

"Gastrointestinal toxicity is a major hurdle in oncology and targeted therapeutics, yet conventional systems struggle to differentiate regional and cellular-state sensitivities," noted Keith Murphy, Executive Chairman at VivoSim Labs. "Our latest intestinal data show that NAMKind Intestine regional tissue architecture with multiparametric readouts provides close correlation with known clinical outcomes. This system provides biopharma developers with an unprecedented lens to evaluate epithelial barrier integrity, optimize lead candidates, and align with modern regulatory frameworks like the FDA Modernization Act 2.0."

Presentation Details

Poster #P419 (Liver): NAMkind™ Liver Multiparametric Analysis Detects Liver Injury Signals in Drug Candidates Discontinued During Early Clinical Development
Poster #P421 (Intestine): NAMkind™ Intestine Profiles Region- and Culture-State-Dependent Epithelial Liabilities of CDK Inhibitors and Tubulin Inhibitor-Linked ADCs
Conference: American College of Toxicology (ACT) Annual Meeting, San Antonio, TX
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fresha Pushes Beauty Bookings Into AI Search Channels

Updated Category News Views 17

A haircut search is turning into a distribution fight, and Fresha has planted itself squarely in the middle of it. The company’s new Partner Network pushes its beauty and wellness marketplace beyond its own app and website into Google Search, Google Maps, Google’s AI experiences, ChatGPT, Claude, and eventually Alexa. That sounds like another glossy AI announcement...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 85

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
Live Nation Tests Creator Content With Morgan Jay Series

Updated Category News Views 57

A comedian turning crowd work into songs is hardly a boardroom event, but this one has a useful wrinkle: Live Nation Studios put financing behind it. Morgan Jay and Austin-based agency Hello Party launched Music Therapy with Morgan Jay on YouTube on November 18, with Kam Patterson opening the season. The show pairs Jay and celebrity guests for loose conversation,...

Continue Reading
ROBOTERA Puts Humanoid Robots Into Logistics Night Work

Updated Category News Views 76

Midnight warehouse work is where a humanoid robot has to quit posing and earn its keep. ROBOTERA arrived at the 2026 APEC CEO Summit with a useful answer to the usual shiny-robot nonsense: it says its machines are already working in logistics centers, handling parcel induction and taking on repetitive, physically demanding shifts that people understandably do not line up...

Continue Reading
WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 104

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
SKINformed Bets on Skin Longevity Over Quick Fixes

Updated Category News Views 41

Wrinkle panic has been a very profitable racket for a long time, and SKINformed is trying to sidestep it. The physician-founded skincare brand is planting its flag on “SKINgevity,” a term it uses to describe long-term skin health rather than a frantic hunt for an overnight rewind. That is a sensible read on where beauty consumers appear to be headed: less appetite for...

Continue Reading
Gildan Lawsuit Puts Revenue Quality Under a Harsh Lens

Updated Category News Views 16

Inventory can hide a multitude of sins until somebody counts the boxes, and that is the ugly question hanging over Gildan Activewear. A federal securities class action alleges the company inflated reported sales and organic-growth figures by pushing excess product into wholesaler and distributor channels. Those are allegations, not findings of fact, and investors ought to...

Continue Reading
NKT’s Q3 Margin Holds Up as Capacity Spending Bites

Updated Category News Views 70

Steel, copper and giant cable drums do not make for a pretty quarterly story, but NKT’s numbers have a sturdier backbone than the headline revenue dip suggests. The company delivered EUR 111 million of operational EBITDA in Q3 2026, down from EUR 119 million a year earlier, while its margin at standard metal prices edged up to 16.6% from 16.4%. That is not fireworks. It...

Continue Reading
Makers Nutrition Backs Families Through Friends of Karen

Updated Category News Views 9

A thousand dollars in gift cards can look modest beside the noise of holiday marketing, but it lands differently when a family is carrying the weight of a child’s life-threatening illness. Makers Nutrition, a Hauppauge, New York-based private-label and custom supplement manufacturer, has donated $1,000 in gift cards to Friends of Karen for the nonprofit’s annual...

Continue Reading
Kuaishou’s AI Push Meets a Brutal Earnings Reality

Updated Category News Views 111

Kuaishou just put a very expensive wrinkle in its AI story. The third-quarter figures are not a minor wobble: revenue dropped 11.1% year over year to RMB31.6 billion, gross margin slid from 54.7% to 48.2%, and the company swung from a RMB4.5 billion profit to a RMB959 million loss. For holders of 01024, that is the sort of earnings release that demands less daydreaming...

Continue Reading

Top 5 Most Recently Viewed Articles

BMO Continues to Support United Natural Foods with Price Target

Updated Category News Views 79

BMO Capital Markets Maintains Support for United Natural Foods BMO Capital Markets has reaffirmed its position regarding United Natural Foods (NYSE: UNFI), assigning a Market Perform rating with a price target set at $23.00. This decision came after productive discussions held with UNFI's senior executives, including CEO Sandy Douglas and CFO Matteo Tarditi, focusing on...

Continue Reading
HONOR's Ambitious Shift to AI Device Ecosystem Strategy

Updated Category News Views 202

HONOR's Bold New Strategy for AI Device Ecosystem In an ambitious move, global technology brand HONOR has laid out a comprehensive strategy to transform from a traditional smartphone manufacturer into a leader in the AI device ecosystem. This announcement marks a significant pivot towards embracing advanced technologies designed to maximize human potential. The new...

Continue Reading
Roche's Strategic Move: Acquiring 89bio for Innovative Therapies

Updated Category News Views 254

Roche's Strategic Acquisition of 89bio Roche's recent decision to acquire 89bio, a clinical-stage biopharmaceutical company, highlights its commitment to enhancing treatment options for patients suffering from metabolic diseases. This acquisition centers around 89bio’s innovative therapy, pegozafermin, which is showing promise for treating moderate to severe Metabolic...

Continue Reading
Baby Safety Alliance Elevates Parent Confidence in Products

Updated Category News Views 137

Baby Safety Alliance Strengthens Trust for Parents The Baby Safety Alliance is excited to announce a significant expansion of its Verification Program. This vital initiative, previously recognized as the JPMA Certification Program, aims to simplify the process for parents seeking safe and reliable products for their babies and children. Growth of the Verification Program...

Continue Reading
Ken Kendrick: A Journey of Resilience and Recognition

Updated Category News Views 646

Ken Kendrick’s Recognition by the Horatio Alger Association Ken Kendrick, the managing general partner of the Arizona Diamondbacks, has recently been honored by the Horatio Alger Association, which has selected him for its Member Class of 2025. This prestigious recognition is awarded to individuals who have overcome personal and professional adversities, showcasing...

Continue Reading